MX2010012480A - Composicion farmaceutica adaptada para administrarse oralmente y proceso para su preparación para su prevencion y tratamiento, del sindrome del intestino irritable, a base de un odificador dela motalidad intestinal y a-d- galactosidasa. - Google Patents

Composicion farmaceutica adaptada para administrarse oralmente y proceso para su preparación para su prevencion y tratamiento, del sindrome del intestino irritable, a base de un odificador dela motalidad intestinal y a-d- galactosidasa.

Info

Publication number
MX2010012480A
MX2010012480A MX2010012480A MX2010012480A MX2010012480A MX 2010012480 A MX2010012480 A MX 2010012480A MX 2010012480 A MX2010012480 A MX 2010012480A MX 2010012480 A MX2010012480 A MX 2010012480A MX 2010012480 A MX2010012480 A MX 2010012480A
Authority
MX
Mexico
Prior art keywords
treating
pharmaceutical composition
galactosidase
bowel syndrome
irritable bowel
Prior art date
Application number
MX2010012480A
Other languages
English (en)
Inventor
John Claude Savoir Vilboeuf
Roberto Bernardo Escudero
Original Assignee
Posi Visionary Solutions Llp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46084558&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2010012480(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Posi Visionary Solutions Llp filed Critical Posi Visionary Solutions Llp
Priority to MX2010012480A priority Critical patent/MX2010012480A/es
Priority to UY0001033732A priority patent/UY33732A/es
Priority to PE2013001061A priority patent/PE20140379A1/es
Priority to KR1020137015555A priority patent/KR20140037798A/ko
Priority to AU2011329917A priority patent/AU2011329917A1/en
Priority to US13/885,629 priority patent/US20150150953A1/en
Priority to CA2818130A priority patent/CA2818130A1/en
Priority to PCT/MX2011/000139 priority patent/WO2012067482A2/es
Priority to JP2013539789A priority patent/JP2013542986A/ja
Priority to CN2011800651365A priority patent/CN103392000A/zh
Priority to EP11841178.4A priority patent/EP2641968A4/en
Priority to BR112013012102A priority patent/BR112013012102A2/pt
Priority to RU2013127273/15A priority patent/RU2013127273A/ru
Priority to ARP110104273A priority patent/AR083889A1/es
Publication of MX2010012480A publication Critical patent/MX2010012480A/es
Priority to CL2013001332A priority patent/CL2013001332A1/es
Priority to CR20130220A priority patent/CR20130220A/es
Priority to DO2013000109A priority patent/DOP2013000109A/es
Priority to ECSP13012643 priority patent/ECSP13012643A/es
Priority to ZA2013/04157A priority patent/ZA201304157B/en
Priority to MA36003A priority patent/MA34730B1/fr
Priority to CO13143132A priority patent/CO6811847A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Una composición o formulación farmacéutica en forma de tableta, tableta recubierta, cápsula o polvo para reconstituir para su uso en el síndrome de intestino irritable, también conocido como síndrome de colon irritable, a base de un modificador de la motilidad intestinal y de la enzima a-D-galactosidasa.
MX2010012480A 2010-11-16 2010-11-16 Composicion farmaceutica adaptada para administrarse oralmente y proceso para su preparación para su prevencion y tratamiento, del sindrome del intestino irritable, a base de un odificador dela motalidad intestinal y a-d- galactosidasa. MX2010012480A (es)

Priority Applications (21)

Application Number Priority Date Filing Date Title
MX2010012480A MX2010012480A (es) 2010-11-16 2010-11-16 Composicion farmaceutica adaptada para administrarse oralmente y proceso para su preparación para su prevencion y tratamiento, del sindrome del intestino irritable, a base de un odificador dela motalidad intestinal y a-d- galactosidasa.
UY0001033732A UY33732A (es) 2010-11-16 2011-11-14 Composición farmacéutica a base de modificador de la motilidad intestinal y alfa-d-galactosidasa para el tratamiento del síndrome del intestino irritable
RU2013127273/15A RU2013127273A (ru) 2010-11-16 2011-11-15 ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, АДАПТИРОВАННАЯ ДЛЯ ОРАЛЬНОГО ВВЕДЕНИЯ, И СПОСОБ ЕЕ ПОЛУЧЕНИЯ ДЛЯ ПРЕДОТВРАЩЕНИЯ И ЛЕЧЕНИЯ СИНДРОМА РАЗДРАЖЕННОГО КИШЕЧНИКА НА ОСНОВЕ МОДИФИКАТОРА МОТОРИКИ КИШЕЧНИКА И ФЕРМЕНТА α-D-ГАЛАКТОЗИДАЗЫ
EP11841178.4A EP2641968A4 (en) 2010-11-16 2011-11-15 ORAL ADMINISTRATIVE PHARMACEUTICAL COMPOSITION FOR THE PREVENTION AND TREATMENT OF REIZDARY SYNDROME WITH AN INNSTIMAL MOBILITY MODEL AND ALPHA-D-GALACTOSIDASE AND METHOD OF PREPARING THEREOF
BR112013012102A BR112013012102A2 (pt) 2010-11-16 2011-11-15 composição farmacêutica adaptada para ser administrada oralmente em forma de comprimido, comprimido revestido, cápsula ou pó para reconstituir, com aplicação em distúrbios intestinais, processo para preparar uma composição farmacêutica e uso de uma composição farmacêutica
AU2011329917A AU2011329917A1 (en) 2010-11-16 2011-11-15 Orally administered pharmaceutical composition and preparation method thereof, for the prevention and treatment of irritable bowel syndrome, comprising an intestinal motility modifier and alpha-D-galactosidase
US13/885,629 US20150150953A1 (en) 2010-11-16 2011-11-15 PHARMACEUTICAL COMPOSITION ADAPTED FOR ORAL ADMINISTRATION AND THE PROCESS FOR ITS PREPARATION, FOR THE PREVENTION AND TREATMENT OF IRRITABLE BOWEL SYNDROME, BASED ON AN INTESTINAL MOTILITY MODIFIER AND a-D-GALACTOSIDASE
CA2818130A CA2818130A1 (en) 2010-11-16 2011-11-15 Orally administered pharmaceutical composition and preparation method thereof, for the prevention and treatment of irritable bowel syndrome, comprising an intestinal motility modifier and a-d-galactosidase
PCT/MX2011/000139 WO2012067482A2 (es) 2010-11-16 2011-11-15 COMPOSICIÓN FARMACÉUTICA ADAPTADA PARA ADMINISTRARSE ORALMENTE Y PROCESO PARA SU PREPARACIÓN, PARA PREVENCIÓN Y TRATAMIENTO DEL SÍNDROME DE INTESTINO IRRITABLE, A BASE DE UN MODIFICADOR DE LA MOTILIDAD INTESTINAL Y α-D-GALAGTOSIDASA
JP2013539789A JP2013542986A (ja) 2010-11-16 2011-11-15 過敏性腸症候群の予防と治療のための、腸運動調整剤とα−Ｄ−ガラクトシダーゼとを含む経口投与用医薬組成物及びその調製方法
CN2011800651365A CN103392000A (zh) 2010-11-16 2011-11-15 用于预防和治疗肠易激综合征的、包含肠能动性调节剂和α-D-半乳糖苷酶的口服给药的药物组合物及其制备方法
PE2013001061A PE20140379A1 (es) 2010-11-16 2011-11-15 Composicion farmaceutica adaptada para administrarse oralmente y proceso para su preparacion, para prevencion y tratamiento del sindrome de intestino irritable, a base de un modificador de la motilidad intestinal y alfa-d-galactosidasa
KR1020137015555A KR20140037798A (ko) 2010-11-16 2011-11-15 장 운동성 조절제 및 α-D-갈락토시다아제를 포함하는, 과민성 장 증후군의 예방 및 치료를 위한, 경구 투여용 약제학적 조성물 및 그의 제조 방법
ARP110104273A AR083889A1 (es) 2010-11-16 2011-11-16 COMPOSICION FARMACEUTICA ADAPTADA PARA ADMINISTRARSE ORALMENTE Y PROCESO PARA SU PREPARACION, PARA PREVENCION Y TRATAMIENTO DEL INTESTINO IRRITABLE A BASE DE UN MODIFICADOR DE LA MOTILIDAD INTESTINAL Y a-D-GALACTOSIDASA
CL2013001332A CL2013001332A1 (es) 2010-11-16 2013-05-14 Composicion farmaceutica adaptada para administrarse oralmente, a base de un modificador de la motilidad intestinal y alfa-d-galactosidasa; proceso para su preparacion; y uso en la prevencion y el tratamiento del sindrome de intestino irritable.
CR20130220A CR20130220A (es) 2010-11-16 2013-05-14 COMPOSICIÓN FARMACÉUTICA ADAPTADA PARA ADMINISTRARSE ORALMENTE Y PROCESO PARA SU PREPARACIÓN, PARA PREVENCIÓN Y TRATAMIENTO DEL SÍNDROME DE INTESTINO IRRITABLE, A BASE DE UN MODIFICADOR DE LA MOTILIDAD INTESTINAL Y a-D-GALAGTOSIDASA
DO2013000109A DOP2013000109A (es) 2010-11-16 2013-05-16 COMPOSICIÓN FARMACÉUTICA ADAPTADA PARA ADMINISTRARSE ORALMENTE Y PROCESO PARA SU PREPARACIÓN, PARA PREVENCIÓN Y TRATAMIENTO DEL SÍNDROME DE INTESTINO IRRITABLE, A BASE DE UN MODIFICADOR DE LA MOTILIDAD INTESTINAL Y a-D- GALACTOSIDASA.
ECSP13012643 ECSP13012643A (es) 2010-11-16 2013-05-27 COMPOSICION FARMACEUTICA ADAPTADA PARA ADMINISTRARSE ORALMENTE Y PROCESO PARA SU PREPARACION, PARA PREVENCION Y TRATAMIENTO DEL SINDROME DE INTESTINO IRRITABLE, A BASE DE UN MODIFICADOR DE LA MOTILIDAD INTESTINAL Y a-DGALACTOSIDASA
ZA2013/04157A ZA201304157B (en) 2010-11-16 2013-06-06 Orally administered pharmaceutical composition and preparation method thereof,for the prevention and treatment of irritable bowel syndrome,comprising an intestinal motility modifier and a-d-galactosidase
MA36003A MA34730B1 (fr) 2010-11-16 2013-06-10 Composition pharmaceutique adaptée à l'administration par voie orale et son procédé de préparation avec un modificateur de la motilité intestinale et une a-d-galagtosidase, utilisation de ladite composition pharmaceutique pour la prévention et le traitement du syndrome de l'intestin irritable
CO13143132A CO6811847A2 (es) 2010-11-16 2013-06-14 Composicíón farmacéutica adaptada para administrarse oralmente y proceso para su preparación, para prevención y tratamiento del síndrome de intestino irritable, a base de un modificador de la motilidad intestinal y a-d-galactosidasa

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MX2010012480A MX2010012480A (es) 2010-11-16 2010-11-16 Composicion farmaceutica adaptada para administrarse oralmente y proceso para su preparación para su prevencion y tratamiento, del sindrome del intestino irritable, a base de un odificador dela motalidad intestinal y a-d- galactosidasa.

Publications (1)

Publication Number Publication Date
MX2010012480A true MX2010012480A (es) 2012-05-16

Family

ID=46084558

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010012480A MX2010012480A (es) 2010-11-16 2010-11-16 Composicion farmaceutica adaptada para administrarse oralmente y proceso para su preparación para su prevencion y tratamiento, del sindrome del intestino irritable, a base de un odificador dela motalidad intestinal y a-d- galactosidasa.

Country Status (21)

Country Link
US (1) US20150150953A1 (es)
EP (1) EP2641968A4 (es)
JP (1) JP2013542986A (es)
KR (1) KR20140037798A (es)
CN (1) CN103392000A (es)
AR (1) AR083889A1 (es)
AU (1) AU2011329917A1 (es)
BR (1) BR112013012102A2 (es)
CA (1) CA2818130A1 (es)
CL (1) CL2013001332A1 (es)
CO (1) CO6811847A2 (es)
CR (1) CR20130220A (es)
DO (1) DOP2013000109A (es)
EC (1) ECSP13012643A (es)
MA (1) MA34730B1 (es)
MX (1) MX2010012480A (es)
PE (1) PE20140379A1 (es)
RU (1) RU2013127273A (es)
UY (1) UY33732A (es)
WO (1) WO2012067482A2 (es)
ZA (1) ZA201304157B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103622936B (zh) * 2013-12-09 2016-04-13 中国人民解放军广州军区武汉总医院 一种具有抗氧化功能的间苯三酚薄膜衣片及其制备方法
RU2586280C1 (ru) * 2015-04-23 2016-06-10 Федеральное государственное бюджетное научное учреждение "Научный центр проблем здоровья семьи и репродукции человека" Способ комплексной терапии функциональных нарушений пищеварения у детей дошкольного возраста
KR102440862B1 (ko) 2020-02-24 2022-09-06 한림대학교 산학협력단 신규한 고정화 효소를 이용한 올리고당 감소 방법

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995001803A1 (en) * 1993-07-06 1995-01-19 Merck & Co., Inc. H2 antagonist-gastrointestinal motility agent combinations
US20030095926A1 (en) * 1997-10-01 2003-05-22 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the gastrointestinal tract or urinary tract
US20040009234A1 (en) * 2002-07-10 2004-01-15 Meisel Gerard M. Gastrointestinal compositions
CO5790164A1 (es) * 2006-08-10 2007-08-31 Procaps S A Composicion farmaceutica solida que incluye en combinacion un agente regulador de la motilidad intestinal y un agente antiflatulento

Also Published As

Publication number Publication date
CN103392000A (zh) 2013-11-13
EP2641968A4 (en) 2014-04-16
KR20140037798A (ko) 2014-03-27
EP2641968A2 (en) 2013-09-25
RU2013127273A (ru) 2014-12-27
CO6811847A2 (es) 2013-12-16
ZA201304157B (en) 2016-01-27
CR20130220A (es) 2013-09-20
ECSP13012643A (es) 2013-10-31
CA2818130A1 (en) 2012-05-24
DOP2013000109A (es) 2013-11-15
WO2012067482A2 (es) 2012-05-24
UY33732A (es) 2012-06-29
MA34730B1 (fr) 2013-12-03
AR083889A1 (es) 2013-03-27
AU2011329917A1 (en) 2013-06-06
CL2013001332A1 (es) 2014-05-23
PE20140379A1 (es) 2014-03-23
US20150150953A1 (en) 2015-06-04
WO2012067482A3 (es) 2012-07-19
JP2013542986A (ja) 2013-11-28
BR112013012102A2 (pt) 2016-08-16

Similar Documents

Publication Publication Date Title
ZA201601534B (en) Pharmaceutical compositions comprising macrolide diastereomers, methods of their synthesis and therapeutic uses
PH12014502744A1 (en) A pharmaceutical composition containing nicotinic acid and/or nicotinamide and/or tryptophan for positively influencing the intestinal microbiota
GB201106743D0 (en) Novel compounds
AU2010233994A8 (en) Bispecific anti-ErbB-3/anti-c-Met antibodies
AP2012006135A0 (en) Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof.
WO2010151541A8 (en) Polymorphic form d of bazedoxifene acetate and methods of preparing same
MY195343A (en) A Novel Phtalazinone Derivatives and Manufacturing Process Thereof
WO2011104652A3 (en) Veterinary compositions
MX360554B (es) Composiciones que comprenden y metodos que utilizan inhibidores de co-transportadores de glucosa-sodio 1 y 2.
IN2012DN02793A (es)
MX364479B (es) Nuevos derivados de indol y de pirrol, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
ZA201303518B (en) Orally administered pharmaceutical composition for the treatment of irritable bowel syndrome, comprising an intestinal motility modifier, an agent that prevents gas retention, and digestive enzymes, and preparation method thereof
MX2010002506A (es) Compuestos de nicotinamida sustituidos y uso de estos en medicamentos.
MX2010012480A (es) Composicion farmaceutica adaptada para administrarse oralmente y proceso para su preparación para su prevencion y tratamiento, del sindrome del intestino irritable, a base de un odificador dela motalidad intestinal y a-d- galactosidasa.
MX2013013436A (es) Derivados de indol sustituidos para el tratamiento de transtornos inmunologicos.
GB201313575D0 (en) A washing capsule for providing washing compositions to a machine
WO2014122671A3 (en) Solid oral compositions of saxagliptin
TN2013000205A1 (en) ORALLY ADMINISTERED PHARMACEUTICAL COMPOSITION AND PREPARATION METHOD THEREOF, FOR THE PREVENTION AND TREATMENT OF IRRITABLE BOWEL SYNDROME, COMPRISING AN INTESTINAL MOTILITY MODIFIER AND α-D-GALACTOSIDASE
TN2010000243A1 (en) Pharmaceutical composition
IN2015DN02660A (es)
UA93232C2 (uk) Спосіб виготовлення лікарського препарату у формі таблеток на основі міансерину гідрохлориду
UA74882U (uk) Фармацевтична композиція для лікування сексуальної дисфункції
UA111139C2 (uk) Тверді фармацевтичні композиції і способи їхнього отримання

Legal Events

Date Code Title Description
GD Licence granted
FA Abandonment or withdrawal